This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeda, Y. Articles by Mabuchi, H. Search for Related Content PubMed PubMed Citation Articles by Takeda, Y. Articles by Mabuchi, H.

(Hypertension. 1997;30:953-956.)
© 1997 American Heart Association, Inc.

Articles

Brain Nitric Oxide Synthase Messenger RNA in Central Mineralocorticoid Hypertension

Yoshiyu Takeda; Isamu Miyamori; Takashi Yoneda; Kenji Furukawa; Satoru Inaba; Ryoyu Takeda; ; Hiroshi Mabuchi

From the Second Department of Internal Medicine (Y.T., I.M., T.Y., K.F., S.I., H.M.) and Department of Health Sciences (Y.T.), School of Medicine, Kanazawa University, and the KKR Hokuriku Hospital (R.T.), Izumigaoka, Kanazawa 920, Japan.

Correspondence to Yoshiyu Takeda, MD, Second Department of Internal Medicine, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920, Japan.

Abstract The mechanism underlying the central hypertensinogenic effects of mineralocorticoids remains unclear. Given that nitric oxide (NO) is thought to act at autonomic sites in the brain to regulate arterial blood pressure, the effects of the potent mineralocorticoids aldosterone and 19-noraldosterone on the abundance of neuronal NO synthase (nNOS) mRNA in the brain were investigated. Wistar-Kyoto rats received a continuous intracerebroventricular infusion of aldosterone or 19-noraldosterone (5 ng/h) from an implanted osmotic minipump for 4 weeks. Total RNA was purified from microdissected tissue blocks containing the hypothalamus, dorsal medulla, rostral ventrolateral medulla, or caudal ventrolateral medulla, and changes in the abundance of nNOS mRNA were determined with a semiquantitative competitive polymerase chain reaction method. Blood pressure was significantly increased in rats 2, 3, and 4 weeks after the onset of intracerebroventricular aldosterone or 19-noraldosterone infusion compared with that in animals receiving vehicle. Subcutaneous infusion of either mineralocorticoid had no effect on blood pressure. Compared with controls, rats treated with aldosterone or 19-noraldosterone for 4 weeks showed significant decreases in the amount of nNOS mRNA in the hypothalamus and rostral and caudal ventrolateral medulla. These data suggest that reduced nNOS activity may contribute to the increase in blood pressure in rats with central mineralocorticoid-induced hypertension.

Key Words: mineralocorticoid • RNA • nitric oxide • nitric oxide synthase • aldosterone

This article has been cited by other articles:

				J. Y.H. Chan, L.-L. Wang, Y.-M. Chao, and S. H.H. Chan Downregulation of Basal iNOS at the Rostral Ventrolateral Medulla Is Innate in SHR Hypertension, March 1, 2003; 41(3): 563 - 570. [Abstract] [Full Text] [PDF]

				Y. Takeda, T. Yoneda, M. Demura, M. Usukura, and H. Mabuchi Calcineurin Inhibition Attenuates Mineralocorticoid-Induced Cardiac Hypertrophy Circulation, February 12, 2002; 105(6): 677 - 679. [Abstract] [Full Text] [PDF]

				H. E. De Wardener The Hypothalamus and Hypertension Physiol Rev, October 1, 2001; 81(4): 1599 - 1658. [Abstract] [Full Text] [PDF]

				J. Zanzinger Role of nitric oxide in the neural control of cardiovascular function Cardiovasc Res, August 15, 1999; 43(3): 639 - 649. [Abstract] [Full Text] [PDF]